

(19) World Intellectual Property
Organization
International Bureau



05 JUL 2005

(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/062591 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number:
PCT/US2004/000320

(22) International Filing Date: 6 January 2004 (06.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/438,343 6 January 2003 (06.01.2003) US
60/473,246 22 May 2003 (22.05.2003) US

(71) Applicant (for all designated States except US): **OREGON HEALTH AND SCIENCE UNIVERSITY** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MOSES, Ashlee** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US). **FRUH, Klaus** [US/US];

2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US). **KING, Jeffrey, S.** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US). **HICKS, James, B.** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US). **RAGGO, Camillo** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US). **NELSON, Jay** [US/US]; 2525 Sw First Avenue, Suite 120, Mail Code Ad120, Portland, Or 97201 (US).

(74) Agents: **DAVISON, Barry, L.** et al.; 2600 Century Square, 1501 Fourth Avenue, Seattle, WA 98101-1688 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: **METHODS OF TREATMENT AND DIAGNOSIS OF KAPOSI'S SARCOMA (KS) AND KS RELATED DISEASES**

PMO inhibition of KSHV phenotype



(57) Abstract: The present invention uses gene expression profiling, and gene silencing methods to identify and provide a plurality of 'validated' KSHV-induced cellular gene sequences and pathways useful as targets for modulation of KSHV-mediated effects on cellular proliferation and phenotype (e.g., cancer) associated with latent and lytic phases of the Kaposi's sarcoma-associated herpesvirus (KSHV; Human herpesvirus 8; HHV8) life cycle. Particular embodiments provide therapeutic compositions, and methods for modulation of KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype, comprising inhibition of KSHV-induced gene sequences. Additional embodiments provide screening assays for compounds useful to modulate KSHV infection or KSHV-mediated effects on cellular proliferation and phenotype. Further embodiments provide diagnostic and/or prognostic assays for KSHV infection.